THIS EVENT HAS BEEN CANCELLED

Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.

Invest, Acquire, Partner & Collaborate to Enhance Targeted Cell Depletion

September 22-23 | Boston, MA

Driving deal-making across targeted cell depletion, checkpoint agonism, tolerance, and oral anti-inflammatory biologics to differentiate, validate, raise capital, and accelerate more durable treatments for autoimmune disease

Register Interest
VIEW THE AGENDA

Brought to you by:

Why Attend?

Returning for its second year, the Autoimmunity & Inflammation Partnering & Investment Summit unites over 70 on-scope and in-strategy companies to increase your success rate, efficiency, and collaborative outcomes.

Unite to:

  • Capitalize on protected face-to-face networking with a 100% aligned audience and the One-on-One Partnering system, to efficiently generate higher-yielding deal opportunities and nurture multiple key relationships in a less competitive forum
  • Understand assessment criteria, data package expectations, and due diligence of pharma and investors, and hear invaluable feedback into your financing or development programs
  • Evaluate the total landscape of emerging assets to discuss collaboration and licensing options with similar stakeholders seeking creative partnerships to validate technologies or de-risk asset development

Networking Format

Pharma & Investor Icebreaker Sessions

Understand Interests Ahead of Meetings, to Present Insights Buyers Want

Don’t miss opening pharma and investor icebreaker panels where Immunology Search & Evaluation, and Investment leads share context into expectations for data packages, stage of assets, targets of interest, and future deal-making trends. Understand nuances between buyers’ interests to see who you align best with or start your 1-to-1 meeting from an advantage point, leading with information that matches these insights into buyers’ interests

HIGH VALUE NETWORKING FORMATS

Select Your Pharma, Sit at Their Table

To protect the opportunity for biotech to sit in front of the attending pharma leads, the pharma icebreaker roundtables follow the opening panel. Across 90 minutes of networking time, biotech select to sit at multiple pharma tables, ensuring the opportunity to ask questions, give introductions, and set context into pipelines or platforms in return

Understand Interests Ahead of Meetings to Present Insights Buyers Want

Don’t miss opening pharma and investor icebreaker panels where Immunology Search & Evaluation, Business Development leads, and VC Partners share context into expectations for data packages, stage of assets, targets of interest, and future deal-making trends. 

Understand nuances between buyers’ interests to see who you align best with, or start your 1-to-1 meeting from an advantageous point, leading with information that matches these insights into buyers’ interests 

Meet Investors, Share your Business Card

To maximize the number of investors you can connect with, the icebreaker speed networking following the venture and investment panel ensures you can swap business cards with all investors present. Join a high table and stay through short rounds of face-to-face investor introductions to ensure those relevant to your company stage, know who you are and can take your business card

Individual Meetings: One-on-One Partnering™

Schedule Meetings in Advance, with the Industry’s Best Partnering Portal

Prepare and pre-arrange your most important meetings by reviewing the full attendee list, and company profiles and reaching out to fill your meeting calendar in advance. Guarantee 30-minute, 1-2-1, and face-to-face time, with pharma present in 70% of meetings and a 30% acceptance rate versus industry standard*

*Statistics an average from 2024 and 2025 Partnering & Investment Summits by Hanson Wade

Testimonials

“This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."

“The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections”

VIEW THE AGENDA
register interest
To the top